Possible role of anti-IL17 drugs in the management of COVID-19: our own experience and literature review

Coronavirus infection COVID-19 is an acute respiratory viral disease caused by a novel beta-coronavirus SARS-CoV-2. In 81 % of cases, mortality in patients associated with the development distress syndrome (ARDS). Another critical challenge cytokine storm, which uncontrolled release proinflammatory mediators due to excessive activation immune system. Cytokine storm another cause high because COVID-19, as it leads multiple organ failure, ARDS and disseminated intravascular coagulation (DIC). Thus, management urgent issue for medical society. Recent research assessed potential role interleukin(IL)-17 pathogenesis patients. Some authors also pointed using anti-IL17 medications severe COVID-19. The present article gives literature review on possible IL-17 our personal experience prescription course